Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LYPLAL1 | Q5VWZ2 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 12/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MET | P08581 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8178419 | 0.82 | DYRK1A (0.46) | LYPLAL1GSK3BTP53 | |
| SCHEMBL12204567 | 0.74 | GSK3B (0.57) | LYPLAL1GSK3BKDM4E | |
| SCHEMBL13461945 | 0.73 | RAB9A (0.46) | GSK3B | |
| SCHEMBL6636334 | 0.71 | LYPLAL1 (0.50) | LYPLAL1GSK3BTP53KDM4E | |
| SCHEMBL27545516 | 0.71 | MEN1 (0.44) | — | |
| SCHEMBL30965 | 0.67 | KDM4E (0.51) | KDM4E | |
| SCHEMBL3491505 | 0.65 | GSK3B (0.83) | GSK3B | |
| SCHEMBL22766338 | 0.65 | PRKCI (0.49) | TP53KDM4E | |
| SCHEMBL31248520 | 0.65 | GSK3B (0.58) | GSK3B | |
| SCHEMBL14486664 | 0.64 | DAO (0.58) | GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1034167-A1 | ALPHA-ALKYLTHIO SUBSTITUTED PYRIMIDINE ETHERS AND THIOETHERS AS VIRAL REVERSE TRANSCRIPTASE INHIBITORS | PHARMACIA & UPJOHN COMPANY (US) | 2000-09-13 | — | — | EP | disclosed |
| WO-1999019304-A2 | ALPHA-ALKYLTHIO SUBSTITUTED PYRIMIDINE ETHERS AND THIOETHERS AS VIRAL REVERSE TRANSCRIPTASE INHIBITORS | PHARMACIA & UPJOHN COMPANY (US) | 1999-04-22 | — | — | WO | disclosed |